Extrapyramidal Signs and Psychiatric Symptoms Predict Faster Cognitive Decline in Alzheimer's Disease

Extrapyramidal symptoms and signs in Alzheimer's disease: Pravalence and correlation with the first symptom

“…However, in the latter study, a group of nondementia, age-and gender-comparable, healthy controls was not assessed. Differences between our results and those reported by other studies, 1,2,11,16,21,[23][24][25][26]28,30,32,34,36 although not dramatic, must be attributed to differences in the characterization of cohorts with respect to neuroleptics use, assessment of EPS with standardized rating scales, spectrum of Parkinsonian symptomatology examined, and source of patients included in the study.…”

Extrapyramidal symptoms and signs in Alzheimer's disease: Pravalence and correlation with the first symptom

“…However, in the latter study, a group of nondementia, age-and gender-comparable, healthy controls was not assessed. Differences between our results and those reported by other studies, 1,2,11,16,21,[23][24][25][26]28,30,32,34,36 although not dramatic, must be attributed to differences in the characterization of cohorts with respect to neuroleptics use, assessment of EPS with standardized rating scales, spectrum of Parkinsonian symptomatology examined, and source of patients included in the study.…”

Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial

“…Our findings are in line with those from various clinical and population-based cohorts in which more rapid progression of dementia symptoms and disability has been observed in subjects suffering from neuropsychiatric symptoms [8,[28][29][30][31]. Of note, in the present study there was no trade-off between this tendency towards faster progression on the one hand and cognitive and functional improvement under EGb 761® treatment on the other; rather we saw undiminished treatment effects across the whole severity spectrum of neuropsychiatric symptoms.…”

Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease

“…A recent review [ 14 ] concluded that the association between age at symptom onset and cognitive progression is not provable. This study did also not identify significant associations between rpAD and education level [ 18 , 34 ] or sex [ 13 , 18 , 28 , 34 ], in line with other reports. A potential explanation could be that the rapid cognitive decline in this disease subtype negates subtle effects from education level.…”

Extrapyramidal symptoms and signs in Alzheimer's disease: Pravalence and correlation with the first symptom

“…However, in the latter study, a group of nondementia, age-and gender-comparable, healthy controls was not assessed. Differences between our results and those reported by other studies, 1,2,11,16,21,[23][24][25][26]28,30,32,34,36 although not dramatic, must be attributed to differences in the characterization of cohorts with respect to neuroleptics use, assessment of EPS with standardized rating scales, spectrum of Parkinsonian symptomatology examined, and source of patients included in the study.…”

Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial

“…Our findings are in line with those from various clinical and population-based cohorts in which more rapid progression of dementia symptoms and disability has been observed in subjects suffering from neuropsychiatric symptoms [8,[28][29][30][31]. Of note, in the present study there was no trade-off between this tendency towards faster progression on the one hand and cognitive and functional improvement under EGb 761® treatment on the other; rather we saw undiminished treatment effects across the whole severity spectrum of neuropsychiatric symptoms.…”

Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease

“…A recent review [ 14 ] concluded that the association between age at symptom onset and cognitive progression is not provable. This study did also not identify significant associations between rpAD and education level [ 18 , 34 ] or sex [ 13 , 18 , 28 , 34 ], in line with other reports. A potential explanation could be that the rapid cognitive decline in this disease subtype negates subtle effects from education level.…”

Extrapyramidal symptoms and signs in Alzheimer's disease: Pravalence and correlation with the first symptom

“…However, in the latter study, a group of nondementia, age-and gender-comparable, healthy controls was not assessed. Differences between our results and those reported by other studies, 1,2,11,16,21,[23][24][25][26]28,30,32,34,36 although not dramatic, must be attributed to differences in the characterization of cohorts with respect to neuroleptics use, assessment of EPS with standardized rating scales, spectrum of Parkinsonian symptomatology examined, and source of patients included in the study.…”

Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial

“…Our findings are in line with those from various clinical and population-based cohorts in which more rapid progression of dementia symptoms and disability has been observed in subjects suffering from neuropsychiatric symptoms [8,[28][29][30][31]. Of note, in the present study there was no trade-off between this tendency towards faster progression on the one hand and cognitive and functional improvement under EGb 761® treatment on the other; rather we saw undiminished treatment effects across the whole severity spectrum of neuropsychiatric symptoms.…”

Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease

“…A recent review [ 14 ] concluded that the association between age at symptom onset and cognitive progression is not provable. This study did also not identify significant associations between rpAD and education level [ 18 , 34 ] or sex [ 13 , 18 , 28 , 34 ], in line with other reports. A potential explanation could be that the rapid cognitive decline in this disease subtype negates subtle effects from education level.…”